Medication info

Sitavis M Tablet 50/1000 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kukje Pharmaceutical Co., Ltd.
Appearance
Dark red oval film-coated tablet
Packaging
28 tablets (14 tablets/PTP×2), 56 tablets (14 tablets/PTP×4)
Approval status
Expired

MFDS item code 201505757 · Approved 2015.08.18

This product's status changed to Expired on 2025.08.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medication should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medication is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Kukje Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes

View approved original text

This medication is used to assist in controlling blood sugar in patients with type 2 diabetes in conjunction with dietary and exercise therapy.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medication should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medication is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains sitagliptin and metformin, which help in controlling blood sugar. First, a serious allergic reaction may occur while taking this medication, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a doctor. Additionally, acute pancreatitis, which is a serious side effect involving inflammation of the pancreas, may occur; if abdominal pain, nausea, or vomiting persists, visit a hospital. This medication should not be administered to patients with poor kidney function, and regular kidney function tests should be conducted if kidney function declines. Particularly in cases that may affect kidney function, such as dehydration, severe infections, heart problems, or acute myocardial infarction, use should be avoided, and discontinuation should be done for a period before and after surgery. It is safer not to use this medication in pregnant women or those who may become pregnant, as well as in nursing mothers. This medication may cause symptoms of hypoglycemia; therefore, caution should be exercised when irregular meals or vigorous exercise occur, and the risk of hypoglycemia may increase when used in combination with other blood glucose-lowering medications. While taking this medication, it is advisable to avoid alcohol consumption, especially for those with poor liver function or alcoholism, as a dangerous condition called lactic acidosis may occur. During treatment with this medication, gastrointestinal disturbances, headaches, upper respiratory infections, and lower Vitamin B12 levels may appear, so regular blood tests are recommended. Lastly, if there are other medications being taken concurrently, drug interactions may occur, so it is essential to inform healthcare professionals of all medications being used. If any suspicious symptoms appear during treatment, it is important to consult a healthcare professional immediately.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
Show 24 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe joint pain with disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disturbance
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air from entering, and keep at room temperature between 1 to 30 degrees Celsius. This will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Dark red oval film-coated tablet

Package unit

28 tablets (14 tablets/PTP×2), 56 tablets (14 tablets/PTP×4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.